{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:12:06Z","timestamp":1788743526668,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Herbalife International of America Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12846-2","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:57:47Z","timestamp":1754056667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip"],"prefix":"10.1038","volume":"15","author":[{"given":"Jacob D.","family":"Larson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Jadalannagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Chaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah","family":"Sliz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Ewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"12846_CR1","unstructured":"Upton, R., et al., Cannabis inflorescence: Cannabis spp. Standards of Identity Analysis and Quality Control 2013."},{"issue":"9","key":"12846_CR2","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/bcp.14038","volume":"85","author":"SA Millar","year":"2019","unstructured":"Millar, S. A. et al. A systematic review of cannabidiol dosing in clinical populations. Br. J. Clin. Pharmacol. 85(9), 1888\u20131900 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"19\u201320","key":"12846_CR3","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1007\/s00213-016-4397-4","volume":"233","author":"DI Brierley","year":"2016","unstructured":"Brierley, D. I. et al. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology 233(19\u201320), 3603\u20133613 (2016).","journal-title":"Psychopharmacology"},{"issue":"2","key":"12846_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1570159X17666190903103923","volume":"18","author":"SG Ferber","year":"2020","unstructured":"Ferber, S. G. et al. The \u201cEntourage Effect\u201d: Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr. Neuropharmacol. 18(2), 87\u201396 (2020).","journal-title":"Curr. Neuropharmacol."},{"key":"12846_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.871962","volume":"13","author":"VL Vernail","year":"2022","unstructured":"Vernail, V. L. et al. Acute cannabigerol administration lowers blood pressure in mice. Front. Physiol. 13, 871962 (2022).","journal-title":"Front. Physiol."},{"issue":"3","key":"12846_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1476-5381.2010.01063.x","volume":"162","author":"S Maione","year":"2011","unstructured":"Maione, S. et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br. J. Pharmacol. 162(3), 584\u2013596 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"12846_CR7","first-page":"1","volume":"44742","author":"R Johnson","year":"2019","unstructured":"Johnson, R. Defining hemp: A fact sheet. Congressional Res. Serv. 44742, 1-12. (2019).","journal-title":"Congressional Res. Serv."},{"key":"12846_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.toxrep.2020.02.014","volume":"7","author":"M Dziwenka","year":"2020","unstructured":"Dziwenka, M. et al. Safety assessment of a hemp extract using genotoxicity and oral repeat-dose toxicity studies in sprague-dawley rats. Toxicol. Rep. 7, 376\u2013385 (2020).","journal-title":"Toxicol. Rep."},{"key":"12846_CR9","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3390\/molecules24091694","volume":"24","author":"LE Ewing","year":"2019","unstructured":"Ewing, L. E. et al. Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model. Molecules 24, 1694 (2019).","journal-title":"Molecules"},{"key":"12846_CR10","unstructured":"FDA-CDER, Epidiolex: Pharmacology review in Application Number 210365. 2018."},{"issue":"8","key":"12846_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20603","volume":"4","author":"JAS Crippa","year":"2021","unstructured":"Crippa, J. A. S. et al. Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the covid-19 pandemic: A randomized clinical trial. JAMA Netw. Open 4(8), e2120603 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"21","key":"12846_CR12","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N. Engl. J. Med. 376(21), 2011\u20132020 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"12846_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.14628","volume":"60","author":"O Devinsky","year":"2019","unstructured":"Devinsky, O. et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia 60(2), 294\u2013302 (2019).","journal-title":"Epilepsia"},{"issue":"20","key":"12846_CR14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky, O. et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N. Engl. J. Med. 378(20), 1888\u20131897 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"12846_CR15","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky, O. et al. Randomized, dose-ranging safety trial of cannabidiol in dravet syndrome. Neurology 90(14), e1204\u2013e1211 (2018).","journal-title":"Neurology"},{"issue":"5","key":"12846_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","volume":"77","author":"I Miller","year":"2020","unstructured":"Miller, I. et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: A randomized clinical trial. JAMA Neurol. 77(5), 613\u2013621 (2020).","journal-title":"JAMA Neurol."},{"issue":"Pt A","key":"12846_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106938","volume":"104","author":"L Taylor","year":"2020","unstructured":"Taylor, L. et al. Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav. 104(Pt A), 106938 (2020).","journal-title":"Epilepsy Behav."},{"issue":"3","key":"12846_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele, E. A. et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial. JAMA Neurol. 78(3), 285\u2013292 (2021).","journal-title":"JAMA Neurol."},{"issue":"10125","key":"12846_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele, E. A. et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391(10125), 1085\u20131096 (2018).","journal-title":"Lancet"},{"issue":"5","key":"12846_CR20","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.2071","volume":"109","author":"PB Watkins","year":"2021","unstructured":"Watkins, P. B. et al. Cannabidiol and abnormal liver chemistries in healthy adults: Results of a phase I clinical trial. Clin. Pharmacol. Ther. 109(5), 1224\u20131231 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"12846_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2023.113778","volume":"176","author":"RG Henderson","year":"2023","unstructured":"Henderson, R. G. et al. Oral toxicity evaluation of cannabidiol. Food Chem. Toxicol. 176, 113778 (2023).","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"12846_CR22","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","volume":"62","author":"T Naftali","year":"2017","unstructured":"Naftali, T. et al. Low-dose cannabidiol is safe but not effective in the treatment for crohn\u2019s disease, a randomized controlled trial. Dig. Dis. Sci. 62(6), 1615\u20131620 (2017).","journal-title":"Dig. Dis. Sci."},{"key":"12846_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/can.2021.0114","volume":"8","author":"R Kaufmann","year":"2021","unstructured":"Kaufmann, R. et al. Observed impact of long-term consumption of oral cannabidiol on liver function in healthy adults. Cannabis Cannabinoid Res. 8, 148 (2021).","journal-title":"Cannabis Cannabinoid Res."},{"key":"12846_CR24","unstructured":"Bashir, A., et al., Liver toxicity. StatPearls 2023."},{"key":"12846_CR25","unstructured":"Lala, V., M. Zubair, and D. Minter Liver function tests. StatPearls 2023."},{"key":"12846_CR26","doi-asserted-by":"publisher","first-page":"8143582","DOI":"10.1155\/2018\/8143582","volume":"2018","author":"TK Marx","year":"2018","unstructured":"Marx, T. K. et al. An assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp. J. Toxicol. 2018, 8143582 (2018).","journal-title":"J. Toxicol."},{"issue":"1","key":"12846_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s42238-022-00153-w","volume":"4","author":"MM Bailey","year":"2022","unstructured":"Bailey, M. M. et al. The effects of subacute exposure to a water-soluble cannabinol compound in male mice. J. Cannabis. Res. 4(1), 44 (2022).","journal-title":"J. Cannabis. Res."},{"issue":"S1","key":"12846_CR28","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1089\/can.2023.0049","volume":"8","author":"J Kulpa","year":"2023","unstructured":"Kulpa, J. et al. Toxicological evaluation and pain assessment of four minor cannabinoids following 14-Day oral administration in rats. Cannabis Cannabinoid Res. 8(S1), S25\u2013S41 (2023).","journal-title":"Cannabis Cannabinoid Res."},{"issue":"4","key":"12846_CR29","first-page":"186","volume":"14","author":"R Kaufmann","year":"2021","unstructured":"Kaufmann, R. Use of a water-soluble form of cannabinol for the treatment of sleeplessness. Int. J. Complement. & Altern. Med. 14(4), 186\u2013190 (2021).","journal-title":"Int. J. Complement. & Altern. Med."},{"issue":"S1","key":"12846_CR30","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1089\/can.2023.0035","volume":"8","author":"J Kulpa","year":"2023","unstructured":"Kulpa, J. et al. Toxicity of cannabigerol: Examination of long-term toxicity and lifespan in caenorhabditis elegans and 14-Day study in sprague dawley rats. Cannabis & Cannabinoid Res. 8(S1), S62\u2013S70 (2023).","journal-title":"Cannabis & Cannabinoid Res."},{"issue":"1","key":"12846_CR31","doi-asserted-by":"publisher","first-page":"2280113","DOI":"10.1080\/15502783.2023.2280113","volume":"20","author":"EN Peters","year":"2023","unstructured":"Peters, E. N. et al. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). J. Int. Soc. Sports Nutr. 20(1), 2280113 (2023).","journal-title":"J. Int. Soc. Sports Nutr."},{"key":"12846_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2022.112828","volume":"161","author":"K Eckstrum","year":"2022","unstructured":"Eckstrum, K. et al. Evaluation of the utility of the Beta Human Liver Emulation System (BHLES) for CFSAN\u2019s regulatory toxicology program. Food Chem. Toxicol. 161, 112828 (2022).","journal-title":"Food Chem. Toxicol."},{"key":"12846_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00204-019-02427-4","volume":"93","author":"AJ Foster","year":"2019","unstructured":"Foster, A. J. et al. Integrated in vitro models for hepatic safety and metabolism: evaluation of a human liver-chip and liver spheroid. Arch. Toxicol. 93, 1021 (2019).","journal-title":"Arch. Toxicol."},{"issue":"517","key":"12846_CR34","doi-asserted-by":"publisher","first-page":"eaax5516","DOI":"10.1126\/scitranslmed.aax5516","volume":"11","author":"KJ Jang","year":"2019","unstructured":"Jang, K. J. et al. Reproducing human and cross-species drug toxicities using a liver-chip. Sci. Transl. Med. 11(517), eaax5516 (2019).","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"12846_CR35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/cts.12969","volume":"14","author":"A Rubiano","year":"2021","unstructured":"Rubiano, A. et al. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin. Transl. Sci. 14(3), 1049\u20131061 (2021).","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"12846_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","volume":"2","author":"L Ewart","year":"2022","unstructured":"Ewart, L. et al. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. Commun. Med. 2(1), 154 (2022).","journal-title":"Commun. Med."},{"key":"12846_CR37","unstructured":"Emulate. Liver-Chip Quad-Culture Protocol. 2023 [cited 2024; EP226 Rev. B:[Available from: https:\/\/emulatebio.com\/wp-content\/uploads\/2023\/08\/EP-226-Rev-B-Liver-Chip-Quad-Culture-Protocol.pdf."},{"key":"12846_CR38","unstructured":"Administration, T.G., Safety of low dose cannabidiol. 2020."},{"key":"12846_CR39","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar, S. A. et al. A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol. 9, 1365 (2018).","journal-title":"Front. Pharmacol."},{"issue":"18","key":"12846_CR40","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1039\/D1LC00348H","volume":"21","author":"J Grant","year":"2021","unstructured":"Grant, J. et al. Simulating drug concentrations in PDMS microfluidic organ chips. Lab. Chip 21(18), 3509\u20133519 (2021).","journal-title":"Lab. Chip"},{"issue":"2","key":"12846_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbrc.2016.11.062","volume":"482","author":"BJ van Meer","year":"2017","unstructured":"van Meer, B. J. et al. Small molecule absorption by PDMS in the context of drug response bioassays. Biochem. Biophys. Res. Commun. 482(2), 323\u2013328 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"12846_CR42","unstructured":"Emulate. Protocol for Emulate Organ-Chips: Compound Distribution Kit. 2019 [cited 2024; EP129 v1.0:[Available from: https:\/\/emulatebio.wpenginepowered.com\/wp-content\/uploads\/2021\/06\/EP129_v1.0_Compound_Distribution_Kit_Protocol.pdf."},{"key":"12846_CR43","doi-asserted-by":"publisher","first-page":"1349590","DOI":"10.3389\/fvets.2024.1349590","volume":"11","author":"W Bookout","year":"2024","unstructured":"Bookout, W. et al. Safety study of cannabidiol products in healthy dogs. Front. Vet. Sci. 11, 1349590 (2024).","journal-title":"Front. Vet. Sci."},{"issue":"7","key":"12846_CR44","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D. et al. Why 90% of clinical drug development fails and how to improve it?. Acta. Pharm. Sin. B. 12(7), 3049\u20133062 (2022).","journal-title":"Acta. Pharm. Sin. B."},{"key":"12846_CR45","unstructured":"Emulate. Ocaliva, Azelaprag, and the Continuing Challenge of Drug-Induced Liver Injury: A Call for Human-Relevant Models. 2024 [cited 2024; Available from: https:\/\/emulatebio.com\/ocaliva-azelaprag-and-the-continuing-challenge-of-drug-induced-liver-injury-a-call-for-human-relevant-models\/."},{"key":"12846_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2024.153885","volume":"506","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. Toxicology 506, 153885 (2024).","journal-title":"Toxicology"},{"key":"12846_CR47","doi-asserted-by":"crossref","unstructured":"Ewing, L.E., et al., Human quad liver-on-chip system as a tool toward bridging the gap between animals and humans regarding toxicology and pharmacology of a cannabidiol-rich cannabis extract. Drug Chem Toxicol 1-8 2024","DOI":"10.1080\/01480545.2024.2388292"},{"issue":"2","key":"12846_CR48","first-page":"131","volume":"4","author":"E Yoon","year":"2016","unstructured":"Yoon, E. et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J. Clin. Transl. Hepatol. 4(2), 131\u2013142 (2016).","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"12","key":"12846_CR49","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/molecules24122256","volume":"24","author":"LE Ewing","year":"2019","unstructured":"Ewing, L. E. et al. Paradoxical patterns of sinusoidal obstruction syndrome-like liver injury in aged female CD-1 mice triggered by cannabidiol-rich cannabis extract and acetaminophen co-administration. Molecules 24(12), 2256 (2019).","journal-title":"Molecules"},{"issue":"1","key":"12846_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","volume":"9","author":"S Atalay","year":"2020","unstructured":"Atalay, S., Jarocka-Karpowicz, I. & Skrzydlewska, E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants 9(1), 21 (2020).","journal-title":"Antioxidants"},{"key":"12846_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2021.104915","volume":"152","author":"AL Dawidowicz","year":"2021","unstructured":"Dawidowicz, A. L., Olszowy-Tomczyk, M. & Typek, R. CBG, CBD, \u03949-THC, CBN, CBGA, CBDA and \u03949-THCA as antioxidant agents and their intervention abilities in antioxidant action. Fitoterapia 152, 104915 (2021).","journal-title":"Fitoterapia"},{"issue":"7","key":"12846_CR52","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/ijms19071992","volume":"19","author":"A Gugliandolo","year":"2018","unstructured":"Gugliandolo, A. et al. In vitro model of neuroinflammation: Efficacy of cannabigerol, a non-psychoactive cannabinoid. Int. J. Mol. Sci. 19(7), 1992 (2018).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"12846_CR53","doi-asserted-by":"publisher","first-page":"NS20200080","DOI":"10.1042\/NS20200080","volume":"5","author":"SR Pereira","year":"2021","unstructured":"Pereira, S. R. et al. Cannabidiol modulation of oxidative stress and signalling. Neuronal Signal. 5(3), NS20200080 (2021).","journal-title":"Neuronal Signal."},{"key":"12846_CR54","first-page":"239784732092294","volume":"4","author":"S Stohs","year":"2020","unstructured":"Stohs, S. & Ray, S. Is cannabidiol hepatotoxic or hepatoprotective: A review. Toxicol. Res. & Appl. 4, 2397847320922944 (2020).","journal-title":"Toxicol. Res. & Appl."},{"issue":"5","key":"12846_CR55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00580-023-03491-0","volume":"32","author":"OA Taiwo","year":"2023","unstructured":"Taiwo, O. A. et al. Dose\u2013response evaluation of cannabichromene on hepato-renal enzyme and non-enzyme biomarkers: the pharmacological controlled study. Comp. Clin. Pathol. 32(5), 811\u2013826 (2023).","journal-title":"Comp. Clin. Pathol."},{"issue":"18","key":"12846_CR56","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3390\/molecules25184036","volume":"25","author":"SA Salami","year":"2020","unstructured":"Salami, S. A. et al. It is our turn to get cannabis high: Put cannabinoids in food and health baskets. Molecules 25(18), 4036 (2020).","journal-title":"Molecules"},{"issue":"9","key":"12846_CR57","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","volume":"85","author":"F Borrelli","year":"2013","unstructured":"Borrelli, F. et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 85(9), 1306\u20131316 (2013).","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"12846_CR58","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/nu15010178","volume":"15","author":"N Aljobaily","year":"2022","unstructured":"Aljobaily, N. et al. Low-dose administration of cannabigerol attenuates inflammation and fibrosis associated with methionine\/choline deficient diet-induced nash model via modulation of cannabinoid receptor. Nutrients 15(1), 178 (2022).","journal-title":"Nutrients"},{"key":"12846_CR59","doi-asserted-by":"publisher","first-page":"3336516","DOI":"10.1155\/2022\/3336516","volume":"2022","author":"F Calapai","year":"2022","unstructured":"Calapai, F. et al. Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evid.-Based Complement. & Altern. Med. 2022, 3336516 (2022).","journal-title":"Evid.-Based Complement. & Altern. Med."},{"key":"12846_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.freeradbiomed.2018.06.023","volume":"124","author":"HY Wu","year":"2018","unstructured":"Wu, H. Y. et al. Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS production. Free Radic. Biol. Med. 124, 311\u2013318 (2018).","journal-title":"Free Radic. Biol. Med."},{"key":"12846_CR61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tox.2016.12.006","volume":"377","author":"N Schultze","year":"2017","unstructured":"Schultze, N. et al. Mitochondrial functions of THP-1 monocytes following the exposure to selected natural compounds. Toxicology 377, 57\u201363 (2017).","journal-title":"Toxicology"},{"issue":"3","key":"12846_CR62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.taap.2007.09.012","volume":"226","author":"HY Wu","year":"2008","unstructured":"Wu, H. Y. et al. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol. Appl, Pharmacol, 226(3), 260\u2013270 (2008).","journal-title":"Toxicol. Appl, Pharmacol,"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12846-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:59:05Z","timestamp":1757336345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12846-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12846"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12846-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28132"}}